

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

March 13, 2024

To,
BSE Limited
Phiroze Jeejeebhoy
Towers Dalal Street
Mumbai - 400 001

Dear Sir / Ma'am,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Elpro International Limited ("the Company") has acquired equity shares of Shilpa Medicare Limited.

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Part A of Schedule III of the SEBI Listing Regulations, is attached as "**Annexure A**".

This is for your information and record.

Thanking you,

For **Elpro International Limited**

Rushabh
Rajen Ajmera

Digitally signed by
Rushabh Rajen Ajmera
Date: 2024.03.13
19:00:33 +05'30'

Rushabh Ajmera
Company Secretary

Encl. as above

Elpro International Ltd

17th Floor, Nirmal, Nariman Point
Mumbai 400 021, India

T +91 22 2202 3075, +91 22 4029 9000
F +91 22 2202 7995

CIN: L51505MH1962PLC012425

Annexure A

Sr. No.	Particulars	Details								
1.	Name of the target entity, details in brief such as size, turnover etc.:	Name of the target entity: Shilpa Medicare Limited Consolidated Turnover as per last audited financials (FY 2022-23): <table border="1"><thead><tr><th>Particulars</th><th>Amount (in Lakhs)</th></tr></thead><tbody><tr><td>Revenue from operations</td><td>1,05,011.24</td></tr><tr><td>Other income</td><td>1,739.97</td></tr><tr><td>Total</td><td>1,06,751.21</td></tr></tbody></table>	Particulars	Amount (in Lakhs)	Revenue from operations	1,05,011.24	Other income	1,739.97	Total	1,06,751.21
Particulars	Amount (in Lakhs)									
Revenue from operations	1,05,011.24									
Other income	1,739.97									
Total	1,06,751.21									
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”:	No								
3.	Industry to which the entity being acquired belongs:	Pharmaceuticals								
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	Investment purpose								
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	N.A.								
6.	Indicative time period for completion of the acquisition:	N.A.								
7.	Nature of consideration - whether cash consideration or share swap and details of the same:	Cash consideration								
8.	Cost of acquisition or the price at which the shares are acquired:	INR 4.05 Crores								

